SUSMEDInc Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Taro Ueno

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	41.4%
Management average tenure	no data
Board average tenure	4yrs

Recent management updates

Recent updates

CEO

Taro Ueno (44 yo)

no data

Tenure

Mr. Taro Ueno is CEO, President and Chairman at SUSMED,Inc.

Board Members

Name	Position	Tenure	Compensation	Ownership
Taro Ueno	Chairman	no data	no data	41.38% ¥ 4.3b
Tomomitsu Motohashi	CTO & Director	5.2yrs	no data	1.01% ¥ 104.9m
Takayuki Kohara	Director of Administration & Director	3.5yrs	no data	0.033% ¥ 3.5m
Kenta Nagao	Audit & Supervisory Board Member	4.2yrs	no data	0.058% ¥ 6.1m
Makiko Yamamoto	Audit & Supervisory Board Member	3.2yrs	no data	no data
Kuniaki Kaga	Independent Outside Director	3.8yrs	no data	0.0030% ¥ 309.1k
Yoshiko Akishima	Chairman of Audit & Supervisory Board	5.2yrs	no data	0.067% ¥ 6.9m

4.0yrs

Average Tenure

53yo

Average Age

Experienced Board: 4263's board of directors are considered experienced (4 years average tenure).

SUSMEDInc Management

Management criteria checks 1/4

Key information

Recent management updates

SUSMED,Inc., Annual General Meeting, Sep 27, 2024

SUSMED,Inc., Annual General Meeting, Sep 29, 2023

Less than half of directors are independent

SUSMED,Inc., Annual General Meeting, Sep 29, 2022

No independent directors

Recent updates

First quarter 2025 earnings released: JP¥9.73 loss per share (vs JP¥8.78 loss in 1Q 2024)

Full year 2024 earnings released: JP¥21.39 loss per share (vs JP¥3.05 loss in FY 2023)

SUSMED,Inc. to Report Q1, 2025 Results on Nov 08, 2024

SUSMED,Inc., Annual General Meeting, Sep 27, 2024

New minor risk - Share price stability

Now 54% undervalued

Forecast to breakeven in 2027

Now 23% undervalued

SUSMED,Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024

Third quarter 2024 earnings released: JP¥7.60 loss per share (vs JP¥16.96 profit in 3Q 2023)

SUSMED,Inc. to Report Q3, 2024 Results on May 10, 2024

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: JP¥3.30 (vs JP¥5.99 loss in 2Q 2023)

Now 21% overvalued

New minor risk - Market cap size

New major risk - Share price stability

SUSMED,Inc. to Report Q2, 2024 Results on Feb 14, 2024

New major risk - Share price stability

First quarter 2024 earnings released: JP¥8.78 loss per share (vs JP¥5.66 loss in 1Q 2023)

SUSMED,Inc. to Report Q1, 2024 Results on Nov 10, 2023

New major risk - Share price stability

Forecast to breakeven in 2025

SUSMED,Inc., Annual General Meeting, Sep 29, 2023

SUSMED,Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: JP¥5.99 loss per share (vs JP¥5.40 loss in 2Q 2022)

SUSMED,Inc. to Report Q2, 2023 Results on Feb 10, 2023

Less than half of directors are independent

Full year 2022 earnings released: JP¥15.87 loss per share (vs JP¥21.65 loss in FY 2021)

SUSMED,Inc. to Report Q1, 2023 Results on Nov 11, 2022

SUSMED,Inc., Annual General Meeting, Sep 29, 2022

Full year 2022 earnings released: JP¥15.87 loss per share (vs JP¥21.65 loss in FY 2021)

SUSMED,Inc. to Report Q4, 2022 Results on Aug 12, 2022

No independent directors

SUSMED,Inc. to Report Q3, 2022 Results on May 12, 2022

SUSMED,Inc. has completed an IPO in the amount of ¥3.65613 billion.

CEO

Tenure

Board Members

Average Tenure

Average Age